

Pub1 acts as an E6-AP-like protein ubiquitin ligase in the degradation of cdc25

Bradley Nefsky and David Beach¹

Cold Spring Harbor Laboratory, 1 Bungtown Road,
Cold Spring Harbor, NY 11724, USA

¹Corresponding author

The level of the mitotic activating tyrosine phosphatase cdc25 is regulated by both transcriptional and post-transcriptional mechanisms in the fission yeast *Schizosaccharomyces pombe*. We have found that cdc25 is ubiquitinated and have cloned *pub1*, a gene which regulates this event. Pub1 contains a region highly homologous to the putative catalytic domain of the human protein ubiquitin ligase E6-AP. Disruption of *pub1* elevates the level of cdc25 protein *in vivo* rendering cells relatively resistant to the cdc25-opposing tyrosine kinases *wee1* and *mik1*. In addition, loss of *wee1* activity in a *pub1*-disruption background results in a lethal premature entry into mitosis which can be rescued by loss of *cdc25* function. A ubiquitin–thioester adduct of *pub1* was isolated from fission yeast and disruption of *pub1* dramatically reduced ubiquitination of cdc25 *in vivo*. These results suggest that *pub1* directly ubiquitinates cdc25 *in vivo*.

Keywords: cdc25/cell cycle/protein degradation/*S.pombe* ubiquitination

Introduction

The eukaryotic cell cycle is regulated by the sequential activation of a series of cyclin-dependent kinases (CDKs) (reviewed in Norbury and Nurse, 1992; King *et al.*, 1994; Morgan, 1995). The fission yeast *Schizosaccharomyces pombe* contains a single archetypal CDK known as *cdc2* (reviewed in Forsburg and Nurse, 1991). *cdc2* is activated both by association with various cyclin subunits and by phosphorylation on Thr167 (Gould *et al.*, 1991; Solomon *et al.*, 1992; Fesquet *et al.*, 1993; for review see Forsburg and Nurse, 1991). The mitotic activity of *cdc2* is inhibited by phosphorylation of Tyr15 by the tyrosine kinases *wee1* and *mik1* (Russell and Nurse, 1987; Gould and Nurse, 1989; Morla *et al.*, 1989; Featherstone and Russell, 1991; Lundgren *et al.*, 1991; Parker *et al.*, 1992). The tyrosine phosphatase *cdc25* dephosphorylates this residue, activating *cdc2* and initiating mitosis (Russell and Nurse, 1986; Gould and Nurse, 1989; Dunphy and Kumagai, 1991; Gautier *et al.*, 1991; Lundgren *et al.*, 1991; Millar *et al.*, 1992). Homologues of *cdc25* are required for entry into mitosis in a number of different organisms, suggesting that this regulatory mechanism is well conserved (Heald *et al.*, 1993; King *et al.*, 1994).

The level of *cdc25* in *S.pombe* accumulates through the cell cycle until late mitosis or G₁ when it rapidly decreases

(Ducommun *et al.*, 1990; Moreno *et al.*, 1990). This pattern of accumulation is reminiscent of mitotic cyclins which are degraded by the ubiquitin system (Glotzer *et al.*, 1991; Seufert *et al.*, 1995). The ubiquitin system targets molecules for degradation by reversible covalent modification with a polyubiquitin chain (reviewed in Finley and Chau, 1991; Ciechanover, 1994). Polyubiquitinated proteins are degraded by the 26S proteasome in an ATP-dependent fashion. Protein ubiquitination involves the activation and subsequent transfer of ubiquitin to a lysine of the target molecule through a series of transiently formed thioester-ubiquitinated intermediates. Initially, an ATP-dependent high-energy thioester bond is formed between the C-terminus of ubiquitin and a cysteine residue in the ubiquitin-activating enzyme (E1). Ubiquitin is then passed in an energy-neutral reaction to a ubiquitin-conjugating enzyme (UBC) or E2, to which it is also covalently bound via a thioester linkage. Although the E2 enzymes are capable of directly ubiquitinating artificial target molecules *in vitro*, the specificity of this reaction *in vivo* appears to require a third component, a protein ubiquitin ligase (E3). To date, two protein ubiquitin ligases have been cloned, *Saccharomyces cerevisiae* UBR1 and human E6-AP (Bartel *et al.*, 1990; Huibregtse *et al.*, 1993a). These two proteins appear to function by completely different mechanisms. UBR1 seems to act as a docking site for both the relevant UBC and target molecules in N-end rule-dependent degradation (Dohmen *et al.*, 1991; Varshavsky, 1992). It has been implicated in the degradation of GPA1, the alpha subunit of a heterotrimeric G protein in *S.cerevisiae* (Madura and Varshavsky, 1994). E6-AP transfers ubiquitin from the relevant E2 to a lysine residue of its target through an E6-AP ubiquitin–thioester intermediate (Scheffner *et al.*, 1995). E6-AP binds high-risk human papillomavirus E6 oncoprotein in HPV-infected human cells (Huibregtse *et al.*, 1991). The E6–E6-AP complex binds and ubiquitinates p53. The resulting degradation of p53 is a key step in HPV-dependent oncogenesis (Crook *et al.*, 1991; Scheffner *et al.*, 1991; Wrede *et al.*, 1991; Scheffner *et al.*, 1993).

In this report we show that *cdc25* is ubiquitinated in fission yeast and have cloned *pub1*, an E6-AP-like protein ubiquitin ligase involved in this process. Pub1 has a region highly homologous to the putative catalytic domain of E6-AP and forms a ubiquitin thioester adduct *in vivo*. Disruption of the *pub1* gene post-transcriptionally elevates *cdc25* protein levels *in vivo* and dramatically reduces *cdc25* ubiquitination. The data suggest that *pub1* directly ubiquitinates *cdc25 in vivo*.

Results

The putative catalytic domain of E6-AP is conserved in *pub1*

Pub1 was fortuitously identified in a screen originally designed to detect novel *S.pombe* tyrosine kinases (see




Fig. 1. The amino acid sequence of *pub1*. The 766 amino acid sequence deduced from the *pub1* cDNA is indicated in the conventional single letter code. The CaLB domain is underlined with a single bar. The region of homology with the putative E6-AP catalytic domain is underlined with a double bar. The putative nucleotide-binding site is shaded.

Materials and methods) (Lindberg *et al.*, 1988; Druker *et al.*, 1989; Lindberg and Pasquale, 1991). It is encoded by a single 2.9 kb message as determined by Northern blot analysis (Figure 4A). Sequence analysis of the 2847 bp *pub1* cDNA revealed a 766 amino acid open reading frame (ORF) (Figure 1). *In vitro* transcription and translation of this cDNA gave rise to an 85 kDa protein, consistent with the size of the predicted ORF (Figure 4B). The human protein ubiquitin ligase E6-AP is the most similar protein of known function in the GenBank database. It is 32% identical to *pub1* (Figure 2). The protein ubiquitin ligase activity of E6-AP requires the formation of a thioester intermediate between the cysteine residue 33 amino acids from its C-terminus and the C-terminus of ubiquitin (Scheffner *et al.*, 1995). The site of E6-AP thiol ubiquitination and the region surrounding this residue are conserved in *pub1* (Figures 1 and 2). Cysteine 734 is the putative site of thioester formation in *pub1*. *Pub1* lacks the sequence required for E6 binding and has only slight similarity to

the region of E6-AP shown to be required for p53 binding by deletion analysis (Huibregtse *et al.*, 1993b). A blast search of GenBank revealed three proteins of unknown function which share quite extensive homology with *pub1* throughout their ORFs: the *S.cerevisiae* protein RSP5 (71% identical), the human protein D42055 (47% identical) and the mouse protein NEDD4 (40% identical) (Kumar *et al.*, 1992; Huibregtse *et al.*, 1995). The 10 proteins identified by a blast search of GenBank to be most similar to *pub1* have the same conserved C-terminal domain found in both E6-AP and *pub1* (Figure 1). These proteins may define an E6-AP-like family of protein ubiquitin ligases (Scheffner *et al.*, 1995).

Further examination of the *pub1* sequence revealed both a Ca^{2+} -dependent lipid-binding domain (CaLB) and a putative ATP-binding site near the N-terminus (Figures 1 and 3). The CaLB domain is a sequence motif conserved in a set of proteins which translocate to phospholipid membranes in a Ca^{2+} -dependent fashion *in vivo* including protein kinase C (PKC), the Ras GTPase activating protein (GAP) and cytosolic phospholipase A_2 (Figure 3) (Clark *et al.*, 1991). We have found that a purified fusion protein between maltose-binding protein and *pub1* dramatically increases its affinity for hydrophobic column matrices in the presence of Ca^{2+} (data not shown). This suggests that *pub1* may also translocate to a phospholipid membrane in a Ca^{2+} -dependent fashion *in vivo*.

The *pub1* gene was physically mapped by probing a collection of contiguous cosmid clones spanning the *S.pombe* genome with *pub1* cDNA (Mizukami *et al.*, 1993). Three overlapping cosmids, 323, 437 and 1187, hybridized to our probe indicating that *pub1* is on the right arm of chromosome 1 near the centromere. Two adjacent *NotI* sites and *cut7* are the closest distal markers to the gene.

A *pub1* disruption was constructed by replacing a 948 bp *SalI*-*NsiI* fragment of the *pub1* ORF with the *ura4* gene (Figure 4D). This construct effectively disrupts about two thirds of the *pub1* ORF including the putative protein ubiquitin ligase domain. A linear fragment containing the disrupted *pub1* gene was introduced into the diploid strain SP 826 (Table I). Stable *Ura*⁺ transformants were recovered by screening for 5-fluoroorotic acid (FOA) sensitivity and Southern blot analysis confirmed that most of those carried one copy of the *pub1*-disruption allele (*pub1::ura4*) and one copy of the wild-type gene (data not shown). The diploid heterozygous for the *pub1* disruption produced four viable spores indicating that *pub1* is not essential for vegetative growth. Southern blot analysis of the *Ura*⁺ haploid cells confirmed that they carried only the disrupted *pub1* gene (Figure 4C).

Genetic interactions with *wee1* and *cdc25*

Cells bearing a *pub1* disruption divide at a cell size noticeably smaller than wild-type. A similar, though more pronounced phenotype can be observed in cells which have lost *wee1* function or are overproducing *cdc25* (Nurse, 1975; Russell and Nurse, 1987). To determine if *pub1* regulated either *cdc25* or *wee1* activity we tested for an interaction between *pub1* and these genes (Table II).

wee1-50 is a temperature-sensitive recessive loss-of-function allele of the non-essential gene *wee1* (Nurse, 1975; Nurse and Thuriaux, 1980). At restrictive tempera-

pub1	416	KVRRNHIFED--SYAE-IMRQSATDLKKRLMIKFDGEDGLDYGGLSREYFFLL	465
E6-AP	525	KVRRDHIIDDALVRLMIAMENPADLKKQLYVEFEGEQGVDEGGVSKPEFFQLV	577
pub1	466	SHEMFNPFYCLFEYSSVDNYTLQINPHSGINPEHLNYPKFFIGRVIGLAIFHRR	518
E6-AP	578	VEEIFNPDIGMFTY-DESTKLFWFNP-S--SFETEGQFTLIGIVLGLAIYNNC	626
pub1	519	FVDAFFVVSFYKMLIQKKVTLQDMESMDAEYRSLVWILDNDITGVLD--LTF	569
E6-AP	627	ILDVHFPMVVYRKLKMGKKGLFVDLGDSDHPVLYQSLKDLLEYVGNVEDDMMITF	679
pub1	570	-SVEDNCFGEVVTIDLKPNGRNIEVTEENKREYVDLVTVWI-QKRIEEQFNAP	620
E6-AP	680	QISQTNLFGNPMMDLKENGDKIPITNENRKEFVNLYSDVILNKSVEKQPKAF	732
pub1	621	HEGF-SELIPQELINVFDERELELLIGGISEIDMEDWKKHTDY-RSYSENDQI	671
E6-AP	733	RRGFHMVVTNESPLKYLFRPEEIELLICGSRNLDQFALEETTEYDGGYTRDSVL	785
pub1	672	IKKFWELMDEWSNEKSRLLQFTTGTSTRIPVNGFKDLQSGDGRKFTIEKAG-	723
E6-AP	786	IREFWEIVHSFTDEQKRLFLQFTTGTDRAPV-G-----G-LGKLMKIAKNGP	831
pub1	724	EPNKLPKAHTCFNRLDLPPTYTSKKDLDHKLKLSIAVEETIGFQGE	766
E6-AP	832	DTERLPTSHTCFNVLLELPEYSSKEKLERLLKAITYAKGFGML	875

Fig. 2. Sequence comparison of fission yeast *pub1* and human protein ubiquitin ligase E6-AP. An amino acid sequence alignment of the *pub1* and E6-AP C-termini by the Needleman-Wunsch method (Intelligenetics) is shown. Identical amino acids appearing in both sequences are shaded. The putative site of *pub1* thioester ubiquitination (Cys734) is indicated by an asterisk. The residues of E6-AP are numbered according to its GenBank file.

PUB1	LYKRDVFRFPDFAVLIV--DGE--QTHITAIK-KTLMPVNNET-VEVNVTDN
CPLA2	M----LDTPDFVLEFIS--TTPDSRKRTRHFN-NDIMFVNNET-VEFILL-DP
PKCg	M---DFNGLSDPYVKLKLIPDPNLTQRKRIVK-ATLMPVNNET-VFVNI-KP
P65a	M-----GQTSDFYVKVVELL--PEKKKKFEKVRH-KTLMPVNEQ-VTFKV--P
P65b	M---DVGGLSDPYVKIHLNMGKRLKPKKFTIKK-HTLMPVNEA-VSFEV--P
GAP	L---PVKHFTNPFYCNLYLN---SVQVAKTHAR--EQQVWAEA-FVRDD-LP
PLCg1	L-PNRGRIVCFPVEIEVAGAEYDSIKKTEFVVDNGLMPVPAKPFHFQISNP
consensus	M-----G-SDFYV-L-L-----K-KTR--K--TLMPVNE--F-F-V--P
	T FA I V R R K R I F I L
	V I H Y I

Fig. 3. CaLB domain comparison. The putative CaLB domain of *pub1* is compared with those of six mammalian proteins and a consensus sequence is determined. Invariant residues are indicated with bold letters. Conserved regions are shaded and gaps are indicated by a dash at the appropriate residue position. The conservative amino acid changes between proteins are indicated in the consensus sequence.

ture cells bearing a *wee1-50* allele undergo mitosis at a cell size significantly smaller than wild-type. Loss of *wee1* function in a *pub1*-disruption background is lethal (Figure 5A). The apparent fragmentation of chromosomes, formation of enucleate cells and occasional septation through the nucleus observed in the double mutant (SP 1209) at restrictive temperature closely resembles the mitotic catastrophe phenotype thought to be the result of premature entry into mitosis (Figure 5B) (Russell and Nurse, 1987; Lundgren *et al.*, 1991). A similar mitotic lethality with *wee1-50* has been observed both in the absence of *mik1* and in cells overproducing *cdc25* (Russell and Nurse, 1986, 1987; Lundgren *et al.*, 1991).

If disruption of *pub1* increases *cdc25* activity *in vivo*, loss of *cdc25* may rescue the *pub1::ura4 wee1-50* synthetic lethality. To test this, a *pub1::ura4 wee1-50 cdc25-22* triple mutant (SP 1211) was constructed. *cdc25-22* is a temperature-sensitive, recessive, loss-of-function allele of *cdc25*. The *pub1::ura4 wee1-50 cdc25-22* triple mutant was viable at restrictive temperature indicating that the mitotic lethality of the *pub1::ura4 wee1-50* double mutant requires *cdc25* function (Figure 5). In contrast, the *mik1::ura4 wee1-50 cdc25-22* triple mutant undergoes lethal premature mitosis at restrictive temperature (Lundgren *et al.*, 1991).

To investigate the interaction between *pub1* and *cdc25* further, a *pub1::ura4 cdc25-22* double mutant (SP 1210) was constructed. At restrictive temperature, this double mutant arrests at the G₂/M boundary with the same terminal phenotype as a *cdc25-22* single mutant (SP 628), i.e. elongated cells with a 2N DNA content (Figure 5).

The *cdc25-22* mutation can be rescued both by overexpression of tyrosine phosphatase activity and by loss of *wee1* function (Fantes, 1979). If disruption of *pub1* is either increasing the activity of a tyrosine phosphatase other than *cdc25* or inhibiting *wee1*, it is insufficient to rescue *cdc25-22*.

Pub1 disruption increases tolerance of *wee1* and *mik1* overproduction

If disruption of *pub1* increases *cdc25* activity *in vivo*, it should increase the resistance of cells to both *wee1* and *mik1* activity. To test this, we overproduced *wee1* and *mik1* under the control of the thiamin-repressible *nmt* promoter in both wild-type and *pub1*-disrupted cells (Maudrell, 1993). The pREP1 plasmid contains a wild-type *nmt* promoter and the pREP41 plasmid a mutated version which reduces the level of expression ~10-fold. Expression of either *wee1* or *mik1* from pREP41 on thiamin-free media arrested wild-type *S.pombe* at the G₂/M boundary preventing colony formation (Table II and Figure 6). In contrast, *pub1::ura4* cells expressing *wee1* or *mik1* from the same vector could readily form colonies in the absence of thiamin (Table II and Figure 6). The level of both *wee1* and *mik1* expression was the same in both wild-type and *pub1*-disrupted strains as determined by Western blot analysis (data not shown). Although more resistant than wild-type, *pub1*-disrupted cells were still sensitive to increased levels of *wee1* and *mik1*. Expression of either kinase from a pREP41 vector increased the size at which these cells divide (data not shown). Increasing *wee1* or *mik1* expression still further using a pREP1 vector arrested *pub1*-disrupted cells, preventing formation of colonies on thiamin-free media (Figure 6) (Maudrell, 1993).

Pub1-disruption elevates *cdc25* protein levels

The genetic evidence suggested that disruption of *pub1* increases *cdc25* activity *in vivo*. To determine if *cdc25* protein levels were affected we examined *cdc25* levels in lysates prepared from asynchronous cultures of both wild-type and *pub1::ura4* strains by Western blot analysis (Figure 7). *cdc25* disruption and overproducing strains were used as controls for antibody specificity. The level of *cdc25* in asynchronously growing *pub1::ura4* cells is




Fig. 4. The *pub1* transcript, translation product and deletion. (A) A Northern blot of total RNA isolated from wild-type (972) *S.pombe* cells grown to mid-log in YEA was probed with *pub1* cDNA. The positions of the RNA molecular weight standards used are indicated on the left. (B) The *pub1* cDNA cloned into pBluescript SK- was transcribed and translated *in vitro* in the presence of [³⁵S]methionine. The translation mixture was subjected to electrophoresis in a 10% Laemmli gel alongside ¹⁴C-labeled molecular weight standards and the gel was autoradiographed. The sizes of the molecular weight standards used are indicated on the left. (C) Genomic DNA isolated from wild-type (972) (lane 1) and *pub1*-disrupted haploid cells (SP 1207) (lane 2) was digested with *Eco*RI and probed with the 2.1 kb *pub1* *Eco*RI fragment. (D) A schematic of the *pub1* cDNA disruption construct is shown. The *pub1* ORF is indicated by the solid black arrow, the deleted sequence by the gap and the corresponding nucleotide numbers are shown above.

~4-fold higher than in wild-type cells (Figure 7, lanes 1 and 2). Loss of *pub1* did not affect the steady state level of *cdc25* message (data not shown). Thus, the disruption of *pub1* post-transcriptionally increases the level of *cdc25* protein *in vivo*, indicating that *pub1* could act by inhibiting *cdc25* translation or enhancing its degradation.

Cdc25 is ubiquitinated in a *pub1*-dependent fashion

The sequence similarity between *pub1* and the protein ubiquitin ligase E6-AP raised the possibility that *pub1*

Table I. List of *S.pombe* strains

Strain	Genotype
972	<i>h</i> ^{-S}
SP 6	<i>h</i> ^{-S} <i>leu1-32</i>
SP 546	<i>h</i> ^{+N} <i>wee1-50</i>
SP 628	<i>h</i> ^{+N} <i>cdc25-22 leu1-32</i>
SP 826	<i>h</i> ^{+N} / <i>h</i> ^{+N} <i>ade6-210/ade6-216 leu1-32/leu1-32 ura4-D18/ura4-D18</i>
SP 974	<i>h</i> ^{+N} <i>cdc2-3w cdc25::ura4 ura4-D18</i>
SP 1062	<i>h</i> ^{-S} <i>cdc25-22ΔART8-25.4 leu1-32 ura4-</i>
SP 1207	<i>h</i> ^{-S} <i>pub1::ura4 ura4-D18</i>
SP 1208	<i>h</i> ^{+N} <i>pub1::ura4 leu1-32 ura4-D18</i>
SP 1209	<i>h</i> ^{-S} <i>pub1::ura4 wee1-50 ura4-D18</i>
SP 1210	<i>h</i> ^{-S} <i>pub1::ura4 cdc25-22 ura4-D18</i>
SP 1211	<i>h</i> ^{-S} <i>pub1::ura4 wee1-50 cdc25-22 ura4-D18</i>
SP 1212	<i>h</i> ^{-S} <i>mts2 cdc25(HA)₃ leu1-32</i>
SP 1213	<i>h</i> ^{-S} <i>mts2 pub1::ura4 cdc25(HA)₃ leu1-32 ura4-D18</i>

Strain SP 1062 was constructed by stably transforming SP 586 *h*^{-S} *cdc25-22, leu1-32, ura4-* with pART8-25.4 which carries *cdc25* under the strong constitutive ADH promoter control. Strain CFX 109-2R *h*^{+N} *cdc2(HA)₃, leu1-32, ura4-D18* used to construct strains SP 1212 and SP 1213 was a generous gift from D.Conklin. The *cdc25* allele *cdc25(HA)₃* has a triple tandem hemagglutinin epitope inserted in-frame at the *Clal* site of *cdc25*. The resulting construct was integrated into the *S.pombe* genome at the *cdc25-22* site. This allele rescues *cdc25-22* at restrictive temperature (D.Conklin, unpublished results). The *mts2* allele used to construct strains SP 1212 and SP 1213 was a generous gift from N.Hastie.

Table II. Genetic interactions

(A)			
Relevant genotype	25°C	30°C	37°C
<i>pub1::ura4</i>	+	+	+
<i>wee1-50</i>	+	+	+
<i>pub1::ura4, wee1-50</i>	+	+	-(l.m.)
<i>cdc25-22</i>	+	+	-(<i>cdc</i> ⁻)
<i>pub1::ura4, cdc25-22</i>	+	+	-(<i>cdc</i> ⁻)
<i>pub1::ura4, wee1-50, cdc25-22</i>	+	+	+
(B)			
Relevant genotype	+Thiamin	-Thiamin	
<i>pub1</i> ⁺ + pREP41	+	+	
<i>pub1</i> ⁺ + pREP41 <i>wee1</i>	+	-(<i>cdc</i> ⁻)	
<i>pub1</i> ⁺ + pREP41 <i>mik1</i>	+	-(<i>cdc</i> ⁻)	
<i>pub1::ura4</i> + pREP41	+	+	
<i>pub1::ura4</i> + pREP41 <i>wee1</i>	+	+	
<i>pub1::ura4</i> + pREP41 <i>mik1</i>	+	+	
<i>pub1::ura4</i> + pREP1	+	+	
<i>pub1::ura4</i> + pREP41 <i>wee1</i>	+	-(<i>cdc</i> ⁻)	
<i>pub1::ura4</i> + pREP1 <i>mik1</i>	+	-(<i>cdc</i> ⁻)	

l.m., lethal mitosis
cdc⁻, cell cycle arrest with single nuclei and elongated cells. These cells arrest at the G₂/M boundary with a 2N DNA content.

might enhance *cdc25* degradation by ubiquitination. To determine if *cdc25* was ubiquitinated in *S.pombe*, a strain was constructed bearing both hemagglutinin-tagged *cdc25* in place of the wild-type gene and the *mts2* mutation. *mts2* is a temperature-sensitive mutant in the S4 subunit of the 26S proteasome (Gordon *et al.*, 1993). The 26S proteasome is responsible for the degradation of protein ubiquitin conjugates, and these conjugates accumulate in a *mts2* mutant (Finley and Chau, 1991; Gordon *et al.*,





Fig. 5. Pub1 interacts genetically with *wee1* and *cdc25*. (A) Three plates were streaked with strains of the indicated genotypes: *pub1::ura4* (SP1207); *wee1-50* (SP 546); *cdc25-22* (SP 628); *pub1::ura4 cdc25-22* (SP 1210); *pub1::ura4 wee1-50* (SP 1209); *pub1::ura4 cdc25-22 wee1-50* (SP1211). One of the plates was incubated at 20°C for 14 days, another at 25°C for 5 days and the last at 37°C for 5 days. (B) Visualization by Dapi staining of: (1) *pub1::ura4* cells (SP 1207) grown at 25°C; (2) *pub1::ura4* cells (SP1207) grown at 37°C; (3) *pub1::ura4 wee1-50* cells (SP 1209) grown to mid-log at 25°C and then incubated at 37°C for 3 h; (4) *pub1::ura4 cdc25-22* cells (SP 1210) grown to mid-log at 25°C and then incubated at 37°C for 3 h; (5) *pub1::ura4 wee1-50 cdc25-22* (SP 1211) grown to mid-log at 25°C and then incubated for 3 h at 37°C.




Fig. 6. Disruption of *pub1* increases tolerance of *wee1* and *mik1* expression. A wild-type *pub1* strain (SP6) and a *pub1*-disruption strain (SP1208) containing the indicated plasmids were streaked onto either PM + 20 μ M thiamin or PM as shown. The plates were then incubated at 30°C for 6 days.

1993). At both permissive and restrictive temperatures, *mts2* mutants accumulate a ladder of higher molecular weight species of *cdc25* (Figure 8A, lanes 1–4). *cdc25* immunoprecipitates from this strain were analyzed by Western blotting for the presence of ubiquitin. The ladder of higher molecular weight *cdc25* species which accumulate in an *mts2* mutant cross-react with an anti-ubiquitin antibody, indicating that they are ubiquitinated forms of *cdc25* (Figure 8B, lanes 2 and 4). The anti-ubiquitin antibody preferentially recognizes the higher molecular weight forms of ubiquitinated *cdc25* consistent with multiple ubiquitination. No immunological cross-reactivity was detected in isogenic control strains lacking hemagglutinin epitope-tagged *cdc25* (data not shown).

To determine if *pub1* was involved in ubiquitination of *cdc25*, we constructed a *pub1*-disruption *mts2* strain with hemagglutinin-tagged *cdc25* in place of the wild-type gene (SP 1213). Both the higher molecular weight forms of *cdc25* and the anti-ubiquitin cross-reactive species are absent in a *pub1*-deletion background, indicating that

the predominant mechanism for ubiquitination of *cdc25* requires *pub1* (Figure 8A, lanes 5–8, and 8B, lanes 1 and 3). With extended exposure however, a faint ladder of *cdc25* higher molecular weight species can be seen in a *pub1*-disruption background. We estimate that disruption of *pub1* reduces the accumulation of *cdc25* higher molecular weight species 10-fold (data not shown).

Pub1 is thiol ubiquitinated in vivo

The conservation of the putative E6-AP catalytic domain in *pub1* suggested that *pub1* may also employ a thiol ubiquitinated intermediate during catalysis (Scheffner *et al.*, 1993, 1995). We were unable to detect this intermediate in logarithmically growing cells, presumably because it is both unstable and most probably present at low levels. We reasoned that in the absence of target molecules, the components of the ubiquitin cycle which employ ubiquitin thioester intermediates may accumulate in their ubiquitin-charged intermediate form. The formation of new target molecules was blocked by inhibition




Fig. 7. Disruption of *pub1* increases the level of *cdc25* protein *in vivo*. 100 μ g of soluble protein from (lane 1) wild-type cells (972); (lane 2) *pub1*-disrupted cells (SP 1207); (lane 3) *cdc25* disrupted cells (SP 974); and (lane 4) cells overproducing *cdc25* (SP 1062); grown to mid-log in YEA at 30°C were resolved by SDS-PAGE on a 10% Laemmli gel. The resolved proteins were transferred to nitrocellulose and probed with an affinity purified anti-*cdc25* polyclonal antibody.

of translation with cycloheximide followed by a brief incubation to permit the degradation of all accessible target molecules. Since it is recycled, blocking translation should not deplete the cellular stores of ubiquitin (Finley and Chau, 1991).

If thiol-ubiquitinated *pub1* accumulates in cycloheximide-treated cells it should be possible to co-immunoprecipitate the two proteins in a cycloheximide-dependent fashion. In addition, if *pub1* and ubiquitin are linked by a thioester bond, their association should be both refractile to denaturing reagents and labile to reducing reagents. Both hemagglutinin-tagged and untagged *pub1* under the control of the *nmt* promoter in pREP1 were introduced into a *pub1*-disruption strain. Cultures of both strains were shifted to thiamin-free medium for 10 h to induce *pub1* expression after which cycloheximide was added. Lysates were prepared in the absence of reducing agents from both cultures immediately before and 1 h after the addition of cycloheximide. The cells were lysed under strongly denaturing conditions [1% lithium lauryl sulfate (LDS)] to disassociate non-covalent protein interactions. *Pub1* was immunoprecipitated from dilutions of these lysates and the immunoprecipitates divided into two aliquots. One aliquot was incubated and washed in RIPA buffer containing 20 mM DTT to displace and remove thioester bound ubiquitin and the other was treated identically with RIPA buffer lacking DTT. The immunoprecipitates were then incubated in Laemmli sample buffer containing β -mercaptoethanol (β -me) and subjected to electrophoresis on an 8% gel to resolve *pub1* and on an 18% gel to resolve any ubiquitin released by β -me treatment of the samples. The gels were then analyzed by Western blot analysis for the presence of *pub1* (Figure 9C) and ubiquitin (Figure 9D). One hour after treating the cells with cycloheximide, ubiquitin co-immunoprecipitated with *pub1* (Figure 9C and D, lane 4). The absence of ubiquitin in the cycloheximide-treated untagged *pub1* control demonstrated that the co-immunoprecipitation of ubiquitin with *pub1* is specific (Figure 9C and D, lane 5). The association




Fig. 8. *Pub1* is involved in *cdc25* ubiquitination. (A) Cultures of both *pub1+* cells (SP 1212) *h^{ts} mts2.cdc25(HA)₃ leu1-32* and *pub1-* cells (SP 1213) *h^{ts} pub1::ura4 mts2.cdc25(HA)₃ leu1-32 ura4D-18* were grown to mid-log phase at 25°C and then shifted to 37°C. Cell lysates were prepared from both strains after 0, 2, 3 and 4 h at 37°C. 100 μ g of soluble protein from each lysate was resolved on an 8% Laemmli gel, transferred to nitrocellulose and probed with the 12CA5 anti-HA monoclonal antibody to detect *cdc25*. (B) Strains SP 1212 and SP 1213 grown to mid-log phase at 25°C were incubated at 37°C for 3 h and lysed. *cdc25* was immunoprecipitated from each lysate with the affinity purified anti-*cdc25* antibody and the immunoprecipitated proteins resolved on an 8% Laemmli gel. Each sample was run in duplicate: lanes 1 and 3 contain immunoprecipitates from *pub1-* SP 1213 and lanes 2 and 4 contain immunoprecipitates from *pub1+* SP 1212. Lanes 1 and 2 were probed with the 12CA5 anti-HA monoclonal antibody to detect the total *cdc25* present, and lanes 3 and 4 were probed with an anti-ubiquitin polyclonal antibody to detect ubiquitinated *cdc25*.

of ubiquitin with *pub1* was sensitive to reducing agents. Incubating and washing the cycloheximide-treated *pub1* immunoprecipitate with DTT removed the bound ubiquitin (Figure 9C and D, lane 2). In the absence of DTT treatment, ubiquitin remains bound to *pub1* until released by the β -me in the sample buffer (Figure 9C and D, lane 4). Like all thioesters, the association between *pub1* and ubiquitin was also sensitive to 0.1 M NaOH and refractile to 1 M formic acid (data not shown) (Scheffner *et al.*, 1995).

If *pub1* is thiol ubiquitinated, the association between




Fig. 9. Pub1 is thioester ubiquitinated *in vivo*. (A and B) C-terminally HA-tagged pub1 was induced in a SP 1208 + pREP1pub1/HA culture for 10 h at 30°C in PM and then cycloheximide was added. Aliquots of the culture were removed at 0, 15, 30, 60 and 120 min after addition of cycloheximide and lysates prepared in the absence of reducing agents. PAGE samples were then prepared both in the absence (A), and in the presence (B) of β -me. PAGE samples containing 50 μ g of protein prepared in the absence of β -me were subjected to electrophoresis on a modified 8% Laemmli gel at 4°C. SDS-PAGE samples containing 50 μ g of protein prepared in the presence of β -me were subjected to electrophoresis in an 8% Laemmli gel at room temperature. The proteins in both gels were transferred to nitrocellulose and probed with 12CA5 anti-HA monoclonal antibody to detect pub1. (C and D) SP 1208 + pREP1pub1/HA and SP 1208 + pREP1pub1 were grown for 10 h at 30°C in the absence of thiamin to induce *pub1* expression. Cycloheximide was then added and incubation continued for another hour. Lysates were prepared in the absence of reducing agents from both strains immediately before and 60 min after the addition of cycloheximide. The 12CA5 anti-HA monoclonal antibody was used to immunoprecipitate pub1 and the immunoprecipitates were divided into two aliquots. One aliquot was incubated for 1 h at 4°C in RIPA buffer containing 20 mM DTT and then washed in the same buffer (+ DTT). The other aliquot was treated identically with RIPA buffer lacking DTT (-DTT). The immunoprecipitates were subjected to electrophoresis both on an 8% Laemmli gel to resolve pub1 (C) and on an 18% Laemmli gel to resolve ubiquitin released by treatment of thioester ubiquitinated pub1 with the β -me-containing sample buffer (D). The proteins in both gels were transferred to nitrocellulose and probed with either 12CA5 anti-HA antibody for the presence of pub1 (C) or an anti-ubiquitin polyclonal antibody for the presence of free ubiquitin (D).

pub1 and ubiquitin should be coincident with the appearance of a DTT-sensitive, 5–10 kDa higher molecular weight form of pub1. To test this, *pub1*-deletion strains carrying either hemagglutinin-tagged or untagged pub1 in pREP1 were shifted to thiamin-free medium for 10 h to induce *pub1* expression. Cycloheximide was then added and aliquots removed from each culture at the indicated times. Gel samples of lysates from each time point were prepared in both the presence and absence of β -me and subjected to Western blot analysis using the anti-HA

monoclonal antibody 12CA5 to detect pub1. Two more slowly migrating forms of pub1 (a and b) accumulated in cycloheximide-treated cells bearing pREP1pub1/HA (Figure 9A). In the presence of reducing agents, both species are absent (Figure 9B). The decrease in mobility exhibited by pub1-a could be accounted for by the addition of a single molecule of ubiquitin. Pub1-b migrates at the rate predicted for a molecule of approximately twice the molecular weight of pub1. Such a species could be the product of disulfide-bond formation between two pub1 molecules or between pub1 and a protein of approximately the same molecular weight. In the absence of a hemagglutinin tag, no pub1 was detected (data not shown).

The association of ubiquitin with pub1 is refractile to both 1% LDS and 1 M formic acid, sensitive to both DTT and 0.1 M NaOH and co-incident with the appearance of pub1-a, an ~5–10 kDa DTT-sensitive higher molecular weight form of pub1. These observations suggest the presence of a thioester bond between pub1 and ubiquitin *in vivo*.

Discussion

It is becoming increasingly apparent that ubiquitin-dependent protein degradation plays a central role in cell cycle regulation. Cyclins are degraded by the ubiquitin system and the degradation of cyclin B is required to exit mitosis in *Xenopus* (Murray *et al.*, 1989). The metaphase to anaphase transition during mitosis appears to be initiated by sister chromatid separation, an event which seems to require ubiquitin-dependent degradation of an unknown protein (Holloway *et al.*, 1993). In *S.cerevisiae*, the degradation of the *cdc28/clb* inhibitor p40^{SIC1} is required for transition from G₁ to S phase (Schwob *et al.*, 1994). Although p40^{SIC1} has not been shown to be ubiquitinated, its degradation is dependent upon the ubiquitin-conjugating enzyme (E2) *cdc34* (Schwob *et al.*, 1994). Similarly, FAR1, a protein required for pheromone-induced G₁ arrest in *S.cerevisiae* is degraded at the G₁/S transition in a *cdc34*-dependent fashion (McKinney *et al.*, 1993). Although some of the targets and E2s of the ubiquitin degradation system involved in cell cycle regulation have been identified, the protein ubiquitin ligases which determine the specificity of these reactions have not yet been cloned.

The level of *cdc25* protein in fission yeast is tightly regulated by both transcriptional and post-transcriptional mechanisms (Ducommun *et al.*, 1990; Moreno *et al.*, 1990). In this report we have shown that *cdc25* is ubiquitinated in *S.pombe* and we have cloned *pub1*, an E6-AP-related protein ubiquitin ligase involved in this process. Pub1 contains a region homologous to the putative catalytic domain of the human protein ubiquitin ligase E6-AP and forms a ubiquitin thioester *in vivo*. The *pub1* disruption post-transcriptionally increases the level of *cdc25* protein *in vivo* behaving genetically like an activator of *cdc25*.

The simplest model which explains these observations is a direct ubiquitination of *cdc25* by *pub1 in vivo*. Pub1-dependent ubiquitination may require one or more additional components. E6-AP for example, requires the oncogenic HPV E6 protein to both bind and ubiquitinate p53 (Huibregtse *et al.*, 1991, 1993b). In this regard it is interesting to note that *pub1-b* accumulates under the

same conditions and at the same time as does thioester-ubiquitinated *pub1*. *Pub1-b* may be composed of *pub1* crosslinked by disulfide bond to a protein required for *pub1*-dependent ubiquitination. Assuming that *pub1* directly ubiquitinates *cdc25*, the low level *cdc25* ubiquitination observed in a *pub1*-disruption indicates the existence of a second *cdc25* ubiquitination pathway. The ubiquitination of the *mat* $\alpha 2$ repressor in *S.cerevisiae* for example, involves two distinct pathways employing four different ubiquitin-conjugating enzymes (Chen *et al.*, 1993). Alternatively, *pub1* may indirectly regulate *cdc25* ubiquitination by, for example, targeting an inhibitor of *cdc25* ubiquitination. While no direct inhibitors of ubiquitination reactions have been identified to date, *cdc28/cln* kinase activity in *S.cerevisiae* has been shown to inhibit degradation of the mitotic cyclin *clb2* during G_1 (Amon *et al.*, 1994). It is possible that the increase of *cdc25* protein levels observed in a *pub1* disruption may be due to an increase in translation of *cdc25* as opposed to a decrease in its degradation. Given the overwhelming evidence that multiple ubiquitination serves as a general signal for proteolytic degradation, we feel this is a remote possibility (Finley and Chau, 1991; Ciechanover, 1994). However, the role of *pub1* in the ubiquitination of *cdc25* does not preclude it from regulating *cdc25* at some other level, including translation.

Cdc25 is most probably not the only target of *pub1*. Disruption of *pub1* results in pleiotropic effects: the cells clump, are hypersensitive to certain nutrients and grow very poorly on certain carbon sources (our unpublished data). These phenotypes are not obviously attributable to *cdc25* deregulation. In addition, overproduction of *pub1* is lethal in cells with the *cdc2-3w* mutation which do not require *cdc25* function (our unpublished data). The presence of a CaLB domain in *pub1* suggests that under conditions which raise intracellular Ca^{2+} levels, *pub1* may target membrane-bound or -associated proteins. Interestingly, *cdc25A* has been shown to co-localize to the plasma membrane in mouse 3T3 cells (Galaktionov *et al.*, 1995a). We conducted a blast search of GenBank using either E6-AP or *pub1* as query sequence. Of the sequences recovered with homology to the putative catalytic domain of E6-AP, only *pub1* and RSP5 had CaLB domains.

Pub1 represents a novel mechanism for *cdc25* regulation. Loss of *pub1* results in elevated levels of *cdc25* protein and increased *cdc25* activity *in vivo*. With this in mind it is intriguing to note that overexpression of *cdc25* may be oncogenic in humans. Overproduction of human *cdc25A* or *cdc25B* cooperates with either activated Ras or loss of Rb in mouse cells to form oncogenic foci (Galaktionov *et al.*, 1995b). Furthermore, 32% of primary breast tumors in humans were found to overexpress *cdc25B* (Galaktionov *et al.*, 1995b). If a functional homolog of *pub1* exists in humans, its loss may well prove oncogenic.

Materials and methods

Strains and media

All *S.pombe* strains were derived from the wild-type strains originally described by Leupold (1970). All strains used in this study are listed in Table 1. *Schizosaccharomyces pombe* was grown in standard YE, YEA and PM media (Beach *et al.*, 1985) containing additional leucine as described at 150 μ g/ml. Where indicated medium was supplemented

with 20 μ M thiamin. Standard *S.pombe* genetic procedures were followed (Gutz *et al.*, 1974).

Cloning sequencing and mapping *pub1*

A *S.pombe* cDNA library cloned into the *NorI* site of λ ZAP2 was immunologically screened with the anti-phosphotyrosine monoclonal antibody (UBI) (Lindberg *et al.*, 1988; Druker *et al.*, 1989; Lindberg and Pasquale, 1991). 2.5×10^5 plaques were screened and two putative positive clones were identified which were capable of generating anti-phosphotyrosine cross-reactive polypeptides upon induction in *Escherichia coli* as determined by Western blot analysis. *pub1* was one of these genes. The originally isolated *pub1* insert was used to re-screen the λ ZAP2 *S.pombe* cDNA library by hybridization to obtain a full-length cDNA. *In vitro* tyrosine kinase assays of *pub1* lysates and purified fusion proteins failed to detect any tyrosine kinase activity (Wong and Goldberg, 1983; Braun *et al.*, 1984; Casnelli, 1991; Racker, 1991).

A series of unidirectional deletions of both the original *pub1* isolate and full length *pub1* cDNA was constructed in either pBluescript SK- or pBluescript KS- (Henikoff, 1987). Both strands of the cDNA clones were sequenced with a semi-automatic DNA sequencer (ABI 373A DNA sequencer). The predicted amino acid sequence was generated by an Intelligenetics program translation of the cDNA sequence. A blast search of GenBank was then performed to identify proteins with similar sequences. The *pub1* sequence was compared by visual inspection to the consensus sequence of the kinase catalytic domain (Hanks and Quinn, 1991).

We believe the cloning of *pub1* in a screen for tyrosine kinase activity was fortuitous. Although *E.coli* does not contain any tyrosine kinase activity, a phosphoamino acid analysis of total *E.coli* proteins will indicate the presence of phosphotyrosine. This phosphotyrosine is the product of acid hydrolysis of tyrosine-nucleotidylated *E.coli* proteins (Foster *et al.*, 1989). We suspect a similar artifact resulted in the cloning of *pub1*. Depending upon the point of attack, hydrolysis of the nucleotidyl-O-tyrosyl bond can yield two possible pairs of products; either a free tyrosine residue and a nucleotide monophosphate, or a phosphorylated tyrosine and a nucleoside. It has been shown that micrococcal nuclease can catalyze the hydrolysis of the adenylyl-O-tyrosyl moiety of *E.coli* tyrosine adenylylated glutamine synthetase *in vitro* producing a tyrosine phosphorylated protein (Kimura *et al.*, 1989). Expression of *pub1* in *E.coli* might increase either endogenous tyrosine nucleotidylolation or the rate of hydrolysis of these adducts. Either case could produce a sufficient amount of tyrosine-phosphorylated proteins to be detected with an anti-phosphotyrosine antibody in our screen.

The *pub1* gene was physically mapped by probing a collection of contiguous cosmid clones spanning the *S.pombe* genome with the 2.8 kb *pub1* cDNA (Mizukami *et al.*, 1993).

Gene disruption

A 948 bp *Sall*-*NsiI* fragment of the *pub1* cDNA was replaced with the 1.8 kb *ura4* gene. The resulting 3.7 kb disrupted cDNA was introduced into the diploid strain SP 826 and the Ura^+ transformants screened for inability to form single colonies in the presence of FOA. Genomic DNA from FOA-sensitive Ura^+ strains was then screened by Southern blot for disruption of a copy of the *pub1* gene. Colonies from one of these strains were screened by iodine staining for conversion of the mat locus from h^{+N}/h^{+N} to h^{90}/h^{+N} . Tetrads from this diploid strain were then dissected.

Southern and Northern blot analysis

Genomic *S.pombe* DNA was isolated from strains 972 and SP 1207, digested with *EcoRI* and Southern blot analysis was performed (Sambrook *et al.*, 1989; Moreno *et al.*, 1991). The 2.1 kb *EcoRI* fragment from the *pub1* cDNA was used as a probe.

Total *S.pombe* RNA was isolated as previously described (Moreno *et al.* 1991). Full-length *pub1*, *cdc25* and *ura4* were ^{32}P -labeled by random priming and used as probes as indicated in the text.

Epitope tagging of *pub1*

The *pub1* cDNA was used as a template for a PCR which introduced an *NdeI* site at the initiating methionine and a *SpeI* site immediately before the translational stop of the *pub1*. The *NdeI*-*SpeI* *pub1* fragment was then cloned into the *NdeI*-*SpeI* sites of the bacterial expression vector pET5C/HA.1 which contains a single hemagglutinin epitope bounded by an *SpeI* site on the 5' end and a stop codon followed by a *BamHI* site on the 3' end. The resulting construct fused the C-terminus of *pub1* to the 11 amino acid peptide TSPYDVPDYA containing a

single hemagglutinin epitope preceded by the amino acids TS. The N-terminal *NdeI*–*Bam*HI fragment of this epitope-tagged *pub1* was cloned into the *NdeI*–*Bam*HI sites of the *S.pombe* expression vector pREP1 and the C-terminal *Bam*HI fragment was then cloned into the *Bam*HI site of the resulting construct. The final construct pREP1*pub1*HA consists of the *pub1* ORF with a C-terminal 11 amino acid extension containing the HA epitope cloned into the *NdeI*–*Bam*HI sites of pREP1.

Immunoprecipitation and immunoblotting of *cdc25*

Schizosaccharomyces pombe extracts for immunoblotting of *cdc25* were prepared as previously described (Ducommun *et al.*, 1990). Cell pellets were resuspended in twice their volume of buffer I [50 mM Tris–HCl pH 8, 8 mM urea, 1 mM EGTA, 5 mM EDTA, 0.1 mM PMSF, 1 µg/ml leupeptin, 10 µg/ml soybean trypsin inhibitor, 1 µg/ml aprotinin and 10 µg/ml tosyl phenylalanine chloromethyl ketone (TPCK)]. The cells were lysed by vortexing in the presence of glass beads and the soluble proteins were recovered by centrifugation. Samples were immediately removed and boiled for 3 min in Laemmli sample buffer. The protein concentration of the lysate was determined by Bradford dye binding assay and Western blot analysis was performed as previously described (Bradford, 1976; Ausubel *et al.*, 1991). Blots containing untagged *cdc25* were probed with an affinity purified anti-*cdc25* polyclonal antibody B1 (Ducommun *et al.*, 1990). Blots containing hemagglutinin-tagged *cdc25* were probed with 100 ng/ml 12CA5 anti-HA monoclonal antibody (Boehringer Mannheim). In both cases *cdc25* was detected by ECL (Amersham).

To immunoprecipitate *cdc25* we modified the previously described protocol (Ducommun *et al.*, 1990). Cell pellets were resuspended in 4 volumes of ice-cold buffer 2 (25 mM Tris–HCl pH 8.0, 60 mM β-glycerol phosphate, 15 mM *para*-nitrophenylphosphate, 0.1 mM orthovanadate and 0.1% Triton X-100) containing the same protease inhibitors as in buffer I. The cells were lysed by vortexing in the presence of glass beads at 4°C and the extracts immediately made 1% SDS and boiled for 3 min. The extracts were then diluted 10-fold in RIPA buffer lacking SDS and soluble proteins were recovered by centrifugation at 10 000 g for 15 min at 4°C. The protein concentration was then determined by Bradford assay (Bradford, 1976). The lysates were pre-incubated with protein A–agarose (Pierce) for 30 min and centrifuged at 10 000 g for 10 min both at 4°C. Immunoprecipitation was performed using affinity purified anti-*cdc25* polyclonal antibody B1 and the immunoprecipitates was analyzed by Western blot for the presence of both ubiquitinated and hemagglutinin-tagged *cdc25*.

Immunoblot detection of ubiquitin

The same protocol was used to detect both free ubiquitin and ubiquitinated *cdc25*. The gel of interest was transferred to a sheet of 0.2 µm nitrocellulose (Schleicher and Schuell) which has been hydrated overnight in distilled water. After the transfer the nitrocellulose is incubated in distilled water at 100°C for 20 min and then Western blot analysis was performed as previously described (Swerdlow *et al.*, 1986; Ausubel *et al.*, 1991). All subsequent manipulations were done at room temperature. Blots containing ubiquitin were probed with an anti-ubiquitin polyclonal antibody (Sigma) and ubiquitin was detected by ECL.

Immunoblotting and immunoprecipitation of thioester-ubiquitinated *pub1*

Strain SP 1208 bearing either pREP1*pub1*HA or pREP1*pub1* was grown in minimal medium lacking thiamin for 10 h to a density of 10⁷/ml after which cycloheximide was added to a final concentration of 100 µg/ml (Novak and Mitchison, 1987). Immediately before and 15, 30, 60 and 120 min after the addition of cycloheximide 50 ml aliquots were removed from the culture, the cells harvested by centrifugation, washed once with water and the cell pellets kept in a dry ice–ethanol bath until the end of the time course. The cell pellets were then thawed and resuspended in 3 volumes of cold lysis buffer (50 mM HEPES–NaOH pH 7, 1% lithium lauryl sulfate, 150 mM NaCl, 10 mM iodoacetamide, 5 mM EDTA, 1 mM EGTA, 0.1 mM PMSF, 10 µg/ml leupeptin, 10 µg/ml soybean trypsin inhibitor, 1 µg/ml aprotinin and 10 µg/ml TPCK) (Hershko *et al.*, 1982; Haas *et al.*, 1985; Vieira *et al.*, 1985). The cells were lysed by vortexing in the presence of glass beads and the soluble proteins recovered by centrifugation at 10 000 g for 15 min at 4°C. The protein concentration was determined by Bradford assay (Bradford, 1976). Two gel samples of identical protein concentration were prepared from each time point one using standard Laemmli sample buffer and the other a modified Laemmli sample buffer which lacked β-me and had LDS in place of SDS. The standard Laemmli samples were subjected to electrophoresis in an 8% Laemmli gel at room temperature. The other

samples were subjected to electrophoresis at 4°C in a modified Laemmli gel in which LDS is substituted for SDS (McGrath *et al.*, 1991). Both gels were transferred to nitrocellulose and subjected to Western blot analysis with the 12CA5 anti-HA monoclonal antibody as described above.

To immunoprecipitate thioester-ubiquitinated *pub1*, strain SP 1208 containing pREP1*pub1*HA or pREP1*pub1* was grown in minimal medium lacking thiamin at 30°C for 10 h to a density of 10⁷/ml. The culture was then made 100 µg/ml cycloheximide and incubated for an additional hour at 30°C. Aliquots were removed immediately before and 1 h after the addition of cycloheximide. The cells were harvested, washed once with distilled water and kept in a dry ice–ethanol bath until lysis. Lysates were prepared in cold lysis buffer as described above. The lysates were diluted 10-fold with RIPA buffer containing the same protease inhibitors as the lysis buffer and lacking SDS. The soluble proteins were recovered by centrifugation and the protein concentration determined by Bradford assay. Thiol-ubiquitinated *pub1* was immunoprecipitated from 5 mg of soluble lysate protein with the 12CA5 monoclonal antibody. The immunoprecipitates were then split into two equal aliquots. One aliquot was incubated for 1 h at 4°C in RIPA buffer containing both protease inhibitors present in buffer I and 20 mM DTT and then washed twice the same buffer. The other aliquot was treated identically with the same buffer lacking DTT. The beads were resuspended in Laemmli sample buffer and boiled for 3 min. Samples from both aliquots were run on both an 8% gel to detect *pub1* and an 18% gel to detect free ubiquitin. *Pub1* and ubiquitin Westerns were performed as described above.

Miscellaneous

Dapi (4,6-diamidino-2-phenylindole) staining of *S.pombe* cells was done according to Moreno *et al.* (1991).

pub1 was transcribed and translated *in vitro* using the TNT T7 coupled reticulocyte lysate system (Promega) in the presence of ³⁵S Express (NEN).

Acknowledgements

We wish to thank Dr Hastie for his generous gift of the temperature-sensitive *mts2* allele and Dr Conklin for his generous gift of strain CFX 109-2R containing the triply-hemagglutinin-tagged *cdc25* allele. In addition we would like to thank Dr Zhang for generously providing us with plasmid pET5C/HA.1 and Jim Duffy, Phil Renna and Mike Ockler for artistic assistance.

References

- Amon, A., Irniger, S. and Nasmyth, K. (1994) Closing the cell cycle circle in yeast: G2 cyclin proteolysis initiated at mitosis persists until the activation of G1 cyclins in the next cycle. *Cell*, **77**, 1037–1050.
- Ausubel, F.M., Brent, R., Kingston, R.E., Moore, D.D., Seidman, J.G., Smith, J.A. and Struhl, K. (1991) *Current Protocols in Molecular Biology*. Greene/John Wiley, New York.
- Bartel, B., Wunning, I. and Varshavsky, A. (1990) The recognition component of the N-end rule pathway. *EMBO J.*, **9**, 3179–3189.
- Beach, D., Rodgers, L. and Gould, J. (1985) Ran1⁺ controls the transition from mitotic division to meiosis in fission yeast. *Nature*, **300**, 706–709.
- Bradford, M.M. (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein dye binding. *Anal. Biochem.*, **72**, 248–254.
- Braun, S., Raymond, W.E. and Racker, E. (1984) Synthetic tyrosine polymers as substrates and inhibitors of tyrosine-specific protein kinases. *J. Biol. Chem.*, **259**, 2051–2054.
- Casnell, J. (1991) Assay of protein kinases using peptides with basic residues for phosphocellulose binding. *Methods Enzymol.*, **200**, 115–120.
- Chen, P., Johnson, P., Sommer, T., Jentsch, S. and Hochstrasser, M. (1993) Multiple ubiquitin conjugating enzymes participate in the *in vivo* degradation of the yeast MAT α2 repressor. *Cell*, **74**, 357–369.
- Ciechanover, A. (1994) The ubiquitin-proteasome proteolytic pathway. *Cell*, **79**, 13–21.
- Clark, J.C., Lin, L.L., Kriz, R.W., Ramesha, C.S., Sultzman, L.A., Lin, A.Y., Milona, N. and Knopf, J.L. (1991) A novel arachidonic acid-selective cytosolic PLA₂ contains a Ca²⁺-dependent translocation domain with homology to PKC and GAP. *Cell*, **65**, 1043–1051.
- Crook, T., Wrede, D. and Vousden, K.H. (1991) p53 point mutation in

- HPV negative human cervical carcinoma cell lines. *Oncogene*, **6**, 873–875.
- Dohmen,R.J., Madura,K., Bartel,B. and Varshavsky,A. (1991) The N-end rule is mediated by the UBC2 (RAD6) ubiquitin-conjugating enzyme. *Proc. Natl Acad. Sci. USA*, **88**, 7351–7355.
- Druker,B.J., Mamon,H.J. and Roberts,T.M. (1989) Oncogenes, growth factors and signal transduction. *New Engl. J. Med.*, **321**, 1383–1391.
- Ducommun,B., Draetta,G., Young,P. and Beach,D. (1990) Fission yeast cdc25 is a cell cycle regulated protein. *Biochem. Biophys. Res. Commun.*, **167**, 301–309.
- Dunphy,W.G. and Kumagai,A. (1991) The cdc25 protein contains an intrinsic phosphatase activity. *Cell*, **67**, 189–196.
- Fantes,P. (1979) Epistatic gene interactions in the control of division in fission yeast. *Nature*, **279**, 428–430.
- Featherstone,C. and Russell,P. (1991) Fission yeast p107^{wee1} mitotic inhibitor is a tyrosine/serine kinase. *Nature*, **349**, 808–811.
- Fesquet,D. et al. (1993) The MO15 gene encodes the catalytic subunit of a protein kinase that activates cdc2 and other cyclin-dependent kinases (CDKs) through phosphorylation of thr 161 and its homologues. *EMBO J.*, **12**, 3111–3121.
- Finley,D. and Chau,V. (1991) Ubiquitination. *Annu. Rev. Cell Biol.*, **7**, 25–69.
- Forsburg,S. and Nurse,P. (1991) Cell cycle regulation in the yeasts *Saccharomyces cerevisiae* and *Schizosaccharomyces pombe*. *Annu. Rev. Cell Biol.*, **7**, 227–256.
- Foster,R., Thorner,J. and Martin,G.S. (1989) Nucleotidylation, not phosphorylation, is the major source of the phosphotyrosine detected in enteric bacteria. *J. Bacteriol.*, **171**, 272–279.
- Galaktionov,K., Jessus,C. and Beach,D. (1995a) Raf1 interaction with cdc25 phosphatase ties mitogenic signal transduction to cell cycle activation. *Genes Dev.*, **9**, 1046–1058.
- Galaktionov,K., Lee,A.K., Eckstein,J., Draetta,G., Meckler,J., Loda,M. and Beach,D. (1995b) Cdc25 phosphatases as potential human oncogenes. *Science*, **269**, 1575–1577.
- Gautier,J., Solomon,M.J., Booher,R.N., Fernando Bazan,J. and Kirschner,M. (1991) cdc25 is a specific tyrosine phosphatase that directly activates p34^{cdc2}. *Cell*, **67**, 197–211.
- Glotzer,M., Murray,A.W. and Kirschner,M.W. (1991) Cyclin is degraded by the ubiquitin pathway. *Nature*, **349**, 132–138.
- Gordon,C., McGurk,G., Dillon,P., Rosen,C. and Hastie,N.D. (1993) Defective mitosis due to a mutation in the gene for a fission yeast 26S protease subunit. *Nature*, **366**, 355–357.
- Gould,K.L. and Nurse,P. (1989) Tyrosine phosphorylation of the fission yeast cdc2⁺ protein kinase regulates entry into mitosis. *Nature*, **342**, 39–45.
- Gould,K., Moreno,S., Owen,D., Sazer,S. and Nurse,P. (1991) Phosphorylation at thr 167 is required for *Schizosaccharomyces pombe* p34^{cdc2} function. *EMBO J.*, **10**, 3297–3309.
- Gutz,H., Heslot,H., Leupold,U. and Loprieno,N. (1974) *Schizosaccharomyces pombe*. In King,R.C. (ed.), *Handbook of Genetics*. Plenum Press, New York, Vol. 1, pp. 395–446.
- Haas,A.L., Murphy,K.E. and Bright,P.M. (1985) The inactivation of ubiquitin accounts for the inability to demonstrate ATP, ubiquitin-dependent proteolysis in liver extracts. *J. Biol. Chem.*, **260**, 4694–4703.
- Hanks,S.K. and Quinn,A.M. (1991) Protein kinase catalytic domain sequence database: identification of conserved features of primary structure and classification of family members. *Methods Enzymol.*, **200**, 38–62.
- Heald,R., McLoughlin,M. and McKeon,F. (1993) Human wee1 maintains mitotic timing by protecting the nucleus from cytoplasmically activated cdc2 kinase. *Cell*, **74**, 463–474.
- Henikoff,S. (1987) Unidirectional digestion with exonuclease III in DNA sequence analysis. *Methods Enzymol.*, **155**, 156–165.
- Hershko,A., Eytan,E., Ciechanover,A. and Haas,A. (1982) Immunochemical analysis of the turnover of ubiquitin-protein conjugates in intact cells. *J. Biol. Chem.*, **257**, 13964–13970.
- Holloway,S.L., Glotzer,M., King,R.W. and Murray,A.W. (1993) Anaphase is initiated by proteolysis rather than by the inactivation of maturation promoting factor. *Cell*, **73**, 1393–1402.
- Huibregtse,J.M., Scheffner,M. and Howley,P.M. (1991) A cellular protein mediates association of p53 with the E6 oncoprotein of human papillomavirus types 16 or 18. *EMBO J.*, **13**, 4129–4135.
- Huibregtse,J.M., Scheffner,M. and Howley,P.M. (1993a) Cloning and expression of the cDNA for E6-AP, a protein that mediates the interaction of the human papillomavirus E6 oncoprotein with p53. *Mol. Cell Biol.*, **13**, 775–784.
- Huibregtse,J.M., Scheffner,M. and Howley,P.M. (1993b) Localization of the E6-AP regions that direct human papillomavirus E6 binding, association with p53 and ubiquitination of associated proteins. *Mol. Cell Biol.*, **13**, 4918–4927.
- Huibregtse,J.M., Scheffner,M., Beaudenon,S. and Howley,P.M. (1995) A family of proteins structurally and functionally related to the E6-AP ubiquitin-protein ligase. *Proc. Natl Acad. Sci. USA*, **92**, 2563–2567.
- Kimura,K., Nakano,Y. and Matsuoka,K. (1989) O-phosphotyrosyl glutamine synthetase: modification of the nucleotide ligation site of adenylated glutamine synthetase. *J. Biochem. Tokyo*, **105**, 84–87.
- King,R.W., Jackson,P.K. and Kirschner,M.W. (1994) Mitosis in transition. *Cell*, **79**, 563–571.
- Kumar,S., Tomooka,Y. and Noda,M. (1992) Identification of a set of genes with developmentally down regulated expression in the mouse brain. *Biochem. Biophys. Res. Commun.*, **185**, 1155–1161.
- Laemmli,U.K. (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. *Nature*, **227**, 680–685.
- Leupold,U. (1970) Genetical methods for *Schizosaccharomyces pombe*. *Methods Cell Physiol.*, **4**, 169–177.
- Lindberg,R.A. and Pasquale,E.B. (1991) Isolation of cDNA clones that encode active protein tyrosine kinases using antibodies against phosphotyrosine. *Methods Enzymol.*, **200**, 557–564.
- Lindberg,R.A., Thompson,D.P. and Hunter,T. (1988) Identification of cDNA clones that code for protein tyrosine kinases by screening expression libraries with antibodies against phosphotyrosine. *Oncogene*, **3**, 629–633.
- Lundgren,K., Walworth,N., Booher,R., Dembski,M., Kirschner,M. and Beach,D. (1991) Mik1 and wee1 cooperate in the inhibitory tyrosine phosphorylation of cdc2. *Cell*, **64**, 1111–1122.
- Madura,K. and Varshavsky,A. (1994) Degradation of Gα by the N-end rule pathway. *Science*, **265**, 1454–1458.
- Maudrell,K. (1993) Thiamin repressible expression vectors pREP and pRIP for fission yeast. *Gene*, **123**, 127–130.
- McGrath,J.P., Jentsch,S. and Varshavsky,A. (1991) UBA1: an essential yeast gene encoding ubiquitin-activating enzyme. *EMBO J.*, **10**, 227–236.
- McKinney,J.D., Chang,F., Heintz,N. and Cross,F. (1993) Negative regulation of FAR1 at the start of the yeast cell cycle. *Genes Dev.*, **7**, 833–843.
- Millar,J.B.A., Lenaers,G. and Russell,P. (1992) Pyp3 PTPase acts as a mitotic inducer in fission yeast. *EMBO J.*, **11**, 4933–4941.
- Mizukami,T. et al. (1993) A 13kb resolution cosmid map of the 14Mb fission yeast genome by nonrandom sequence-tagged site mapping. *Cell*, **73**, 121–132.
- Moreno,S., Nurse,P. and Russell,P. (1990) Regulation of mitosis by cyclic accumulation of p80^{cdc25} mitotic inducer in fission yeast. *Nature*, **344**, 549–552.
- Moreno,S., Klar,A. and Nurse,P. (1991) Molecular genetic analysis of fission yeast *Schizosaccharomyces pombe*. *Methods Enzymol.*, **194**, 795–823.
- Morgan,D. (1995) Principles of CDK regulation. *Nature*, **374**, 131–134.
- Morla,A.O., Draetta,G., Beach,D. and Wang,J. (1989) Reversible tyrosine phosphorylation of cdc2: dephosphorylation accompanies activation during entry into mitosis. *Cell*, **58**, 193–203.
- Murray,A.W., Solomon,M.J. and Kirschner,M.W. The role of cyclin synthesis and degradation in the control of maturation promoting factor activity. (1989) *Nature*, **393**, 280–286.
- Norbury,C. and Nurse,P. (1992) Animal cell cycles and their control. *Annu. Rev. Biochem.*, **61**, 441–470.
- Novak,B. and Mitchison,J.M. (1987) Periodic cell cycle changes in the rate of CO₂ production in the fission yeast *Schizosaccharomyces pombe* persist after a block to protein synthesis. *J. Cell Sci.*, **87**, 323–325.
- Nurse,P. (1975) Genetic control of cell size at cell division in yeast. *Nature*, **256**, 547–551.
- Nurse,P. and Thuriaux,P. (1980) Regulatory genes controlling mitosis in fission yeast *Schizosaccharomyces pombe*. *Genetics*, **96**, 627–637.
- Parker,L.L., Atherton-Fessler,S. and Pivnicka-Worms,H. (1992) p107^{wee1} is a dual specificity kinase that phosphorylates p34^{cdc2} on tyrosine 15. *Proc. Natl Acad. Sci. USA*, **89**, 2917–2921.
- Racker,E. (1991) Use of synthetic amino acid polymers for assay of protein tyrosine and protein serine kinases. *Methods Enzymol.*, **200**, 107–111.
- Russell,P. and Nurse,P. (1986) cdc25⁺ functions as an inducer of mitotic control of fission yeast. *Cell*, **45**, 145–153.
- Russell,P. and Nurse,P. (1987) Negative regulation of mitosis by wee1⁻, a gene encoding a protein kinase homolog. *Cell*, **49**, 559–567.
- Sambrook,J., Fritsch,E.F. and Maniatis,T. (1989) *Molecular Cloning*. A

- Laboratory Manual*. 2nd edn. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
- Scheffner, M., Munger, K., Byrne, J.C. and Howley, P.M. (1991) The state of the p53 and retinoblastoma genes in human cervical carcinoma cell lines. *Proc. Natl Acad. Sci. USA*, **88**, 5523–5527.
- Scheffner, M., Huibregtse, J.M., Vierstra, R.D. and Howley, P.M. (1993) The HPV-16 E6 and E6-AP complex functions as a ubiquitin protein ligase in the ubiquitination of p53. *Cell*, **75**, 495–505.
- Scheffner, M., Nuber, U. and Huibregtse, J.M. (1995) Protein ubiquitination involving an E1-E2-E3 enzyme ubiquitin thioester cascade. *Nature*, **373**, 81–83.
- Seufert, W., Futcher, B. and Jentsch, S. (1995) Role of a ubiquitin-conjugating enzyme in degradation of S and M phase cyclins. *Nature*, **373**, 78–81.
- Schwob, E., Bohm, T., Mendenhall, M.D. and Nasmyth, K. (1994) The B type cyclin kinase inhibitor p40^{SIC1} controls the G1 to S transition in *S.cerevisiae*. *Cell*, **79**, 233–244.
- Solomon, M.J., Lee, T. and Kirschner, M.W. (1992) Role of phosphorylation on p34^{cdc2} activation, identification of an activating kinase. *Mol. Biol. Cell*, **3**, 13–27.
- Swerdlow, P.S., Finley, D. and Varshavsky, A. (1986) Enhancement of immunoblot sensitivity by heating of hydrated filters. *Anal. Biochem.*, **156**, 147–153.
- Varshavsky, A. (1992) The N-end rule. *Cell*, **69**, 725–735.
- Vierstra, R.D., Langan, S.M. and Haas, A.L. (1985) Purification and initial characterization of ubiquitin from the higher plant *avena sativa*. *J. Biol. Chem.*, **260**, 12015–12021.
- Wong, T.W. and Goldberg, A.R. (1983) In vitro phosphorylation of angiotensin analogues by tyrosyl protein kinases. *J. Biol. Chem.*, **258**, 1022–1025.
- Wrede, D., Tidy, J.A., Crook, T., Lane, D. and Vousden, K.H. (1991) Expression of RB and p53 proteins in HPV-positive and HPV-negative cervical carcinoma cell lines. *Mol. Carcinogen.*, **4**, 171–175.

Received on July 27, 1995; revised on September 29, 1995